NCT00864435View on ClinicalTrials.gov

A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Healthy
Interventions
DRUG

Carvedilol 12.5 mg Tablets, single dose

A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions

DRUG

Coreg® 12.5 mg Tablets , single dose

B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions

Trial Locations (1)

M1L 4S4 / M1L 4R6

Biovail Contract Research (A Division of Biovail Corporation), Toronto

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00864435 - A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter